This workflow automates the critical bottleneck of assessing freedom-to-operate for novel compounds, a process that typically delays projects for weeks with manual legal review. It ingests internal candidate libraries and orchestrates specialized agents to query global patent databases like USPTO and WIPO, parsing claims and descriptions to extract chemical structures and biological targets. The system maps these against your molecules, generating quantified IP risk reports and highlighting white space for novel design. This reduces legal review cycles from months to hours, prevents costly late-stage infringement challenges, and provides a data-driven compass for your medicinal chemistry teams.




